Long, G., & Utikal, J. (2017). Dabrafenib plus trametinib versus dabrafenib monotherapy in patients with metastatic BRAF V600E/K-mutant melanoma: Long-term survival and safety analysis of a phase 3 study. Annals of oncology, 28(7), . https://doi.org/10.1093/annonc/mdx176
Chicago-Zitierstil (17. Ausg.)Long, Georgina, und Jochen Utikal. "Dabrafenib Plus Trametinib Versus Dabrafenib Monotherapy in Patients with Metastatic BRAF V600E/K-mutant Melanoma: Long-term Survival and Safety Analysis of a Phase 3 Study." Annals of Oncology 28, no. 7 (2017). https://doi.org/10.1093/annonc/mdx176.
MLA-Zitierstil (9. Ausg.)Long, Georgina, und Jochen Utikal. "Dabrafenib Plus Trametinib Versus Dabrafenib Monotherapy in Patients with Metastatic BRAF V600E/K-mutant Melanoma: Long-term Survival and Safety Analysis of a Phase 3 Study." Annals of Oncology, vol. 28, no. 7, 2017, https://doi.org/10.1093/annonc/mdx176.